Woodham, Andrew W.
Zeigler, Stad H.
Zeyang, Ella L.
Kolifrath, Stephen C.
Cheloha, Ross W.
Rashidian, Mohammad
Chaparro, Rodolfo J.
Seidel, Ronald D.
Garforth, Scott J.
Dearling, Jason L.
Mesyngier, Maia
Duddempudi, Phaneendra K.
Packard, Alan B. http://orcid.org/0000-0003-0906-1021
Almo, Steven C.
Ploegh, Hidde L. http://orcid.org/0000-0002-1090-6071
Funding for this research was provided by:
Lustgarten Foundation (388167)
Arnold and Mabel Beckman Foundation
American Cancer Society
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (U54GM094662)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI145024)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA198095)
Article History
Received: 10 May 2019
Accepted: 23 July 2020
First Online: 14 September 2020
Competing interests
: The synTac technology was developed in the laboratory of S.C.A. and was licensed to Cue Biopharma, Inc., in which he holds equity, receives royalties and serves as chair of its scientific advisory board. S.J.G. and R.D.S. receive royalties from Cue Biopharma, Inc. The laboratory of H.P. receives financial support in the form of a sponsored research agreement from VIR Biotechnology in the general area of immunity to flu virus, but H.L.P. has no equity stake in VIR.